NIH's last 33 research chimpanzees get a sanctuary date after 10 years
The transfer of 33 animals ends a process that began in 2015, and it sets the template for how institutions retire research programs that outlive their rationale.
The National Institutes of Health will move the last 33 chimpanzees it owns out of a research facility and into a sanctuary next year, the culmination of a process that began in 2015. For executives, it is a live case study in how to retire a long-lived, expensive, reputationally sensitive program without a crisis forcing the decision.
The National Institutes of Health will move the last 33 chimpanzees it owns out of a research facility and into a sanctuary next year, the culmination of a process that began in 2015. That is the story in a single line, and it deserves a beat of silence. The U.S. government is closing the books on a colony of animals that share the overwhelming majority of their DNA with humans, and it is doing it on a schedule rather than in a rush. No scandal forced this. No court order is cited. Just a decade-long unwind reaching its final step.
Hold onto the number 33. It is small, specific, and terminal. The source describes these as the last remaining NIH-owned chimpanzees, which means this transfer empties the federal government's own chimpanzee roster. The word "owned" carries the weight. Historically, NIH has supported chimpanzee work at outside facilities as well as in its own, but ownership is what gives the agency the legal standing and the financial duty to decide where these particular animals live out their lives. When the last 33 leave, the agency's role changes shape: from keeper to payer, from operator to funder of somebody else's sanctuary.
Why did it take from 2015 to next year? Because retiring a chimpanzee is not like closing a lab bench. Chimpanzees can live for decades, they form social groups that cannot be reshuffled casually, and they need veterinary care, housing, and enrichment for the rest of their lives. Sanctuaries have finite capacity and finite budgets, and animals cannot simply be released into the wild after years in captivity. Historically, the slow part of these transfers has not been the decision, it has been the logistics and the money: who pays for lifetime care, and how many animals a given facility can absorb at once without compromising the ones already there.
The science moved first, and the paperwork followed. For much of the 20th century, chimpanzees were used in biomedical research, in part because their genetic proximity to humans made them uniquely useful for studying infectious disease and immunology. Over time, better cell-based assays, genetic tools, and other model systems chipped away at the case for using them, while the ethical argument against keeping highly social, long-lived, cognitively complex animals in laboratories got louder. The mid-2010s also brought a tightening of federal wildlife protections around captive chimpanzees, adding a permitting layer to any move. By the time the retirement process formally began in 2015, the direction was set. What remained was execution.
That execution is where the interesting governance questions live. Lifetime care for a single chimpanzee is expensive, and the bill does not stop when the press release does. Whoever holds the purse strings, whether an agency, a sanctuary, or a mix of both, is signing up for a multi-decade obligation with no revenue attached. For research institutions, that is a useful case study in how to wind down a program that has outlived its rationale: you need a destination, a funding line, a veterinary plan, and a communications strategy, because the reputational cost of a botched handoff is far higher than the cost of doing it properly.
The second-order effects reach well beyond primatology. Every biotech founder, contract research organization, and institutional review board is operating in a world where the bar for justifying animal research keeps rising, and where investors and employees increasingly treat that bar as a reputational test rather than a compliance checkbox. The tools filling the gap, from organoids to organ-on-chip systems to computational models, are becoming a real market, not a science fair project. When a federal agency of NIH's scale completes a decade-long exit from a research model, it signals which way the regulatory and cultural current is running, and it gives cover to everyone downstream who wants to move the same way.
What to watch next year is straightforward. The transfer itself: whether all 33 animals make the move, and whether the receiving sanctuary has the capacity and funding to hold them well. The precedent: whether the same logic gets applied to other species still used in federally supported research, and how quickly. And the money: who ultimately pays for care that could run for decades after the last experiment ended. For executives, the takeaway is not sentimental. It is that long-lived obligations, animal, environmental, or otherwise, do not disappear when a program stops producing. They get transferred, and someone signs for them.
This story's Key Insights and Take-aways are locked.
Create a free account to unlock Executive Actions for one credit.
Register to UnlockAlways free for Executives Club members. Join the Club
More in Science
Anthropic's I.P.O. Made Rank-and-File Researchers Worth Tens of Millions
Researchers who joined just a few years ago are now worth tens of millions, and the windfall resets the pay benchmark for every private A.I. lab still paying in paper.
Sea Lion Culling Strategy Fails: New Model Says Killing Them Won't Save Salmon
The latest research from AAAS overturn a long-held conservation assumption, forcing policymakers to rethink critical resource allocation in marine ecosystems.
Microplastics do more than pile up: they react with water to damage cells
Scientists have found that plastic particles can generate highly reactive molecules in water, a mechanism that could explain links to heart attacks, strokes, and neurological disorders.


